LOS ANGELES & BEIJING--(BUSINESS WIRE)--Abraxis Bioscience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, has now made ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (nab-paclitaxel) available in China for the treatment of patients with metastatic breast cancer. In a global Phase III clinical trial, and in a Phase II clinical trial in China, the tumor response rate for patients who received ABRAXANE for the treatment of metastatic breast cancer was nearly double the response rate compared to patients who received solvent-based paclitaxel.
